KaloBios in free fall after pricing offering at big discount

KaloBios Pharmaceuticals (KBIO) slides 11% premarket on top of 15% during Wednesday's session.

The company's public offering (announced Monday) priced at just $4, nearly 37% below Tuesday's close. (8-K)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs